4th International Symposium on Hepatitis Care in Substance Users
 
07/10/2015
7:30 am - 8:00 amRegistration
Pre-Function Area
8:00 am - 10:30 amOpening Ceremony and Session A: Epidemiology and transmission of HCV infection
The Grand Ballroom One
Chairperson: Dr Joseph Doyle, Burnet Institute, Australia and Eliot Ross Albers, International Network of People Who Use Drugs
8:00 am - 8:10 amWelcome to Country
The Grand Ballroom One
8:10 am - 8:20 amIntroduction to the Conference
The Grand Ballroom One
Associate Professor Jason Grebely, UNSW
8:20 am - 8:30 amOpening from Community Member
The Grand Ballroom One
Annie Madden, Australian Injecting and Illicit Drug Users League (AIVL)
8:30 am - 8:50 amEpidemiological definitions and estimates of populations of PWID with HCV infection
The Grand Ballroom One
Dr Sarah Larney, UNSW

Presentation

8:50 am - 9:10 amEmerging drug patterns and HCV transmission: An increasing cause for concern
The Grand Ballroom One
Professor Julie Bruneau, University of Montreal
9:10 am - 9:30 amMolecular epidemiology of HCV among PWID: New insights into HCV transmission
The Grand Ballroom One
Professor Mel Krajden, British Columbia Centre for Disease Control and University of British Columbia

Presentation

9:30 am - 9:45 amImpact of Opiate Substitution Therapy and Needle Syringe Programmes on Incidence of HCV: A Systematic Review and Meta-Analysis
The Grand Ballroom One
Lucy Platt, London School of Hygiene and Tropical Medicine


9:45 am - 10:00 amCharacterising Hepatitis C Virus Transmission Dynamics in a High-Risk Incarcerated Population
The Grand Ballroom One
Neil Bretana, UNSW

Presentation 

10:00 am - 10:15 amDrawing Them In – Stories from People Who Know
The Grand Ballroom One
Heather McCormack, Hepatitis NSW
10:15 am - 10:30 amHCV Treatment and Prevention: What is the Impact of Current and Scaled-Up Treatment Rates in Selected Sites in Europe?
The Grand Ballroom One
Hannah Woodall, University of Bristol
10:30 am - 11:00 amMorning Tea
Exhibition Hall
11:00 am - 12:45 pmSession B: Prevention and Treatment for HCV: From modelling to implementation
The Grand Ballroom One
Chairperson: Associate Professor Natasha Martin, University of California San Diego
Chairperson: Annie Madden, Australian Injecting and Illicit Drug Users League (AIVL)
11:00 am - 11:15 amStrategies for the prevention of HCV infection
The Grand Ballroom One
Professor Lisa Maher, UNSW
11:15 am - 11:30 amPrevention and Treatment for HCV: From modelling to implementation
The Grand Ballroom One
Professor Matthew Hickman, University of Bristol

Presentation

11:30 am - 11:45 amHCV Treatment and Prevention in the Community - the Treatment and Prevention (TAP) study
The Grand Ballroom One
Professor Margaret Hellard, The Burnet Institute

Presentation

11:45 am - 12:00 pmHCV Treatment and Prevention in the Prison - the Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) Study
The Grand Ballroom One
Professor Andrew Lloyd, UNSW

Presentation

12:00 pm - 12:15 pmThe needs of PWID in the future of HCV care: Implications for treatment as prevention
The Grand Ballroom One
Dr Magdalena Harris, London School of Hygiene and Tropical Medicine

Presentation

12:15 pm - 12:45 pmPanel Discussion
The Grand Ballroom One
12:45 pm - 2:15 pmLunch
Exhibition Hall
12:45 pm - 2:15 pmSatellite Symposium - Abbvie
The Grand Ballroom
2:15 pm - 3:30 pmSession C: Oral Abstracts HCV Epidemiology, Public Health and Modelling
The Grand Ballroom One
Chairperson: Peter Vickerman, University of Bristol
Chairperson: Mary Harrod, NSW Users and AIDS Association
Session D: Oral Abstracts Social and Community Research
The Grand Ballroom Two
Chairperson: Dr Magdalena Harris, London School of Hygiene and Tropical Medicine
Chairperson: Leona Quewezance, All Nations Hope Network
2:15 pm - 2:30 pmOnward Transmission of Hepatitis C Virus Infection among Younger and Older People who Inject Drugs in Vancouver, Canada
The Grand Ballroom One
Brendan Jacka, The Kirby Institute, UNSW Australia

Abstract

The Next Step in Collaborative HCV Care - PWID, Partnerships and Potential to Treat
The Grand Ballroom Two
Jenny Bourke, Hepatitis C Community Clinic

Abstract

2:30 pm - 2:45 pmNetwork-Based Modeling for HCV in US Drug Injectors: Treatment as Prevention
The Grand Ballroom One
Alexei Zelenev, Yale School of Medicine

Abstract

Experiences of PWID Community Network in Linking HCV Testing and Care to Treatment Using Direct Acting Antivirals
The Grand Ballroom Two
Nalinikanta Rajkumar, Community Network for Empowerment (CoNE)

Abstract

2:45 pm - 3:00 pmThe Hepatitis C Epidemic Amongst Men who have Sex with Men: Modelling the Role of Behavioural Risk Heterogeneity and HIV Dependent Mixing Patterns
The Grand Ballroom One
Louis MacGregor, University of Bristol

Abstract


Will the Moment of Hepatitis C Diagnosis Undermine the Promise of New Treatments? An Analysis of Canadian Women's Experiences
The Grand Ballroom Two
Sandi Mitchell, University of Sydney

Abstract

Presentation

3:00 pm - 3:15 pmLiver Disease Knowledge and Acceptability of Non-Invasive Liver Fibrosis Assessment among People who Inject Drugs in the Drug and Alcohol Setting: The Liverlife Study
The Grand Ballroom One
Alison Marshall, Kirby Institute

Abstract

Presentation

“It’s Not Only My Life I Got to Worry About”: Accounts of Needle-Syringe Sharing and Negotiated Safety among Couples who Inject Drugs
The Grand Ballroom Two
Jake Rance, Centre for Social Research in Health

Abstract

3:15 pm - 3:20 pmFemale to Male Ratio of Hepatitis C Virus Incidence; A Systematic Review and Meta Analysis
The Grand Ballroom One
Aryan Esmaeili, Icahn School of Medicine at Mount Sinai

Abstract

Hepatitis See – Low Literacy Hepatitis C Guide for People who Inject Drugs
The Grand Ballroom Two
Clare Mannion, cohealth
Diana Macdonald, Alfred Health

Abstract

3:20 pm - 3:25 pmRelational and Contingent Risk and Harm Reduction: Blood-Borne Virus Prevention and Care in an Urban, Culturally Diverse Neighbourhood
The Grand Ballroom One
Elizabeth Peach, Burnet Institute

Abstract

Empowering Conscious Health Consumers in an Changing Treatment Landscape
The Grand Ballroom Two
Kyle Leadbeatter, Hepatitis NSW

Abstract

Presentation

3:25 pm - 3:30 pmHCV Diagnostic Screening among People who Inject Drugs in Australia
The Grand Ballroom One
Jenny Iversen, The Kirby Institute

Abstract

Presentation

Making Hepatitis C Treatment a National Priority in Georgia through Drug Users Community Advocacy
The Grand Ballroom Two
Paata Sabelashvili, Georgian Harm Reduction Network

Abstract

3:30 pm - 4:00 pmAfternoon Tea
Exhibition Hall
4:00 pm - 5:40 pmSession E: Enhancing Access to Screening and Assessment for HCV infection
The Grand Ballroom One
Chairperson: Dr Jenny Iversen, The Kirby Institute, UNSW
Chairperson: Kim Gates, Northern Territory AIDS and Hepatitis Council,
4:00 pm - 4:20 pmBarriers to HCV screening, diagnosis and assessment: A community perspective
The Grand Ballroom One
Jude Byrne, Australian Injecting and Illicit Drug Users League
4:20 pm - 4:40 pmBarriers to access to screening and assessment of HCV from a patient perspective: A review of the qualitative literature
The Grand Ballroom One
Professor Carla Treloar, UNSW

Presentation

4:40 pm - 5:00 pmInterventions to enhance testing and diagnosis of HCV infection among PWID
The Grand Ballroom One
Professor David Goldberg, Glasgow Caledonian University,

Presentation

5:00 pm - 5:20 pmDiagnosis and treatment of acute HCV infection in the IFN-free era: Does it really matter?
The Grand Ballroom One
Professor Gail Matthews, UNSW

Presentation

5:20 pm - 5:40 pmNon-invasive liver fibrosis assessment: Opportunities for enhanced liver disease assessment and treatment in the drug and alcohol setting
The Grand Ballroom One
Professor Alessio Aghemo, University of Milan

Presentation

6:00 pm - 7:00 pmDrink Reception
Beachside Dojo

08/10/2015
8:00 am - 8:30 amRegistration
Pre-Function Area
8:30 am - 10:45 pmSession F: Treatment of Viral Hepatitis
The Grand Ballroom One
Chairperson: Professor Olav Dalgard, Akershus University Hospital
Chairperson: Tracy Swan, Treatment Action Group
8:30 am - 9:00 amIFN-free therapy for HCV infection: In search of perfectovir
The Grand Ballroom One
Associate Professor Jordan Feld, Physician, University of Toronto

Presentation


9:00 am - 9:20 amInterventions to enhance treatment and adherence to IFN-free HCV therapy among PWID
The Grand Ballroom One
Professor Alain Litwin, Albert Einstein College of Medicine

Presentation

9:20 am - 9:40 amModels of care for management of HCV among PWID
The Grand Ballroom One
Dr Philip Bruggman, Head of internal medicine of Arud, Arud Centres for Addiction Medicine

Presentation

9:40 am - 9:55 amC-EDGE CO-STAR: Adherence and Drug use in HCV-Infected Persons who Inject Drugs (PWID) on Opioid Agonist Therapy (OAT) receiving Grazoprevir + Elbasvir (GZR/EBR) fixed Dose Combination (FDC) for 12 Weeks
The Grand Ballroom One
Professor Greg Dore, UNSW

Presentation

9:55 am - 10:10 amHigh Rates of Sustained Virological Response in People Who Inject Drugs Treated with Sofosbuvir-Based Regimens
The Grand Ballroom One
Professor Alain Litwin, Albert Einstein College of Medicine

Presentation

10:10 am - 10:25 amEvaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS Study, Australia
The Grand Ballroom One
Professor Carla Treloar, UNSW

Presentation

10:25 am - 10:40 amHepatitis C Reinfection Following Sustained Virological Response – A Seven Year Follow-Up of Norwegian Patients Infected through Injecting Drug Use
The Grand Ballroom One
Håvard Midgard, Akershus University Hospital

Presentation

10:40 am - 10:45 amExpanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs: Special Issues from the International Journal of Drug Policy
The Grand Ballroom One
Professor Gerry Stimson, London School of Hygiene and Tropical Medicine and Editor, International Journal of Drug Policy

Presentation

10:45 am - 11:15 amMorning Tea
Exhibition Hall
11:15 am - 12:15 pmSession G: Debate
The Grand Ballroom One
Panellist: Professor Matthew Hickman, University of Bristol
Panellist: Professor Margaret Hellard, The Burnet Institute
Panellist: Karyn Kaplan, Director, International Hepatitis/HIV Policy & Advocacy at Treatment Action Group (TAG)
Panellist: Professor Marina Klein, McGill University Health Centre
Panellist: Andrew Hill, Liverpool University
Panellist: Annie Madden, Australian Injecting and Illicit Drug Users League (AIVL)
Moderator: Professor Carla Treloar, UNSW
12:15 pm - 1:45 pmLunch
Exhibition Hall
12:15 pm - 1:45 pmSatellite Symposium - Gilead
The Grand Ballroom
1:45 pm - 3:00 pmSession H: Oral Abstracts HCV treatment and management
The Grand Ballroom One
Chairperson: Dr John Dillon, University of Dundee
Chairperson: Fiona Poeder, NSW Users and AIDS Association
Session I: Oral Abstracts HCV Epidemiology and Screening
The Grand Ballroom Two
Chairperson: Professor Gerry Stimson, London School of Hygiene and Tropical Medicine and Editor, International Journal of Drug Policy
Chairperson: Charles Henderson, New Zealand Needle Exchange Programme
1:45 pm - 2:00 pmEfficacy of Response-Guided Pegylated Interferon and Ribavirin Therapy for People who Inject Drugs with HCV Genotype 2/3 Infection: The ACTIVATE Study
The Grand Ballroom One
Jason Grebely, The Kirby Institute, UNSW Australia

Abstract

Presentation

Hepatitis C Treatment Uptake among Patients Receiving Opioid Substitution Treatment: A Population Based Study
The Grand Ballroom Two
Håvard Midgard, Akershus University Hospital

Abstract

Presentation

2:00 pm - 2:15 pmEvaluation of Treatment of HCV Infection in Active Injection Drug Users
The Grand Ballroom One
Arshia Alimohammadi, Vancouver Infectious Diseases Centre

Abstract

Presentation

Changes in Injection Drug Use among Recently Hepatitis C Virus-Infected Persons who Inject Drugs Offered Treatment in Montreal, Canada
The Grand Ballroom Two
Andreea Adelina Artenie, Université de Montréal

Abstract

Presentation


2:15 pm - 2:30 pmHow should HCV Antiviral Treatment be Prioritized in the Direct-Acting Antiviral Era? An Economic Evaluation including Individual and Population Prevention Benefits
The Grand Ballroom One
Natasha Martin, University of California San Diego

Abstract

The Potential Prevention Impact of Scaling Up Hepatitis C Virus Treatment for People who Inject Drugs in Prison: A Modeling Analysis for Scotland
The Grand Ballroom Two
Jack Stone, University of Bristol

Abstract


2:30 pm - 2:45 pmHepatitis C Treatment for People who Inject Drugs: Are Direct-Acting Antivirals Cost-Effective?
The Grand Ballroom One
Daniela van Santen, Public Health Service of Amsterdam

Abstract

Presentation

Modelling the Impact of a National Scale Up of Interventions on Hepatitis C Virus Transmission among People who Inject Drugs in Scotland
The Grand Ballroom Two
Hannah Woodall, University of Bristol

Abstract

2:45 pm - 2:50 pmPilot Study: Combining Formal and Peer Education with Fibroscan to Increase HCV Screening and Treatment in Persons Who Inject Drugs
The Grand Ballroom One
Amber Arain, Hasselt University

Abstract

Presentation


Factors Associated with Undiagnosed Hepatitis C Infection among People who Inject Drugs: Missed Opportunities for Diagnostic Testing in The United Kingdom (UK)
The Grand Ballroom Two
Vivian Hope, Public Health England

Abstract

Presentation

2:50 pm - 2:55 pmA Single Tablet Regimen of Ledipasvir + Sofosbuvir is Efficacious and Well-Tolerated Among People Receiving Opiate Substitution Therapy
The Grand Ballroom One
Jason Grebely, The Kirby Institute, UNSW Australia

Abstract

Presentation

Trends in End-Stage Liver Disease among People Receiving Opioid Substitution Therapy with an HCV Notification in New South Wales, Australia between 1993 and 2012
The Grand Ballroom Two
Reem Waziry, Kirby-UNSW

Abstract

Presentation

2:55 pm - 3:00 pmIs Increased HCV Case-Finding Combined With 8-12 Week Interferon-Free Direct-Acting Antiviral Treatment Cost-Effective in UK Prisons? A Dynamic Cost Utility Analysis including Treatment as Prevention Benefits
The Grand Ballroom One
Natasha Martin, University of California San Diego

Abstract

The Community Pop-Up Clinic as a Tool of Engagement for Vulnerable Populations with HCV and HIV Infection
The Grand Ballroom Two
Syune Hakobyan, Vancouver ID Research and Care Centre Society

Abstract

Presentation

3:00 pm - 3:30 pmAfternoon Tea
Exhibition Hall
3:30 pm - 5:10 pmSession J: Important issues for the management HCV among PWID
The Grand Ballroom One
Chairperson: Professor Geert Robaeys, Ziekenhuis Oost Limburg
3:30 pm - 3:40 pmThe Change Project: International stories of PWID with HCV who have received interferon-free treatment
The Grand Ballroom One
3:40 pm - 4:00 pmA national multidisciplinary healthcare network for treatment of hepatitis C in PWID in Slovenia
The Grand Ballroom One
Professor Mojca Maticic, University Medical Centre, Ljubljana

Presentation

4:00 pm - 4:20 pmPeer support for HCV infection: The potential for transformation in the drug and alcohol setting
The Grand Ballroom One
Sione Crawford, Canberra Alliance for Harm Minimisation and Advocacy

Presentation

4:20 pm - 4:40 pmThe Hep C European Initiative: Integrating research, practice and policy
The Grand Ballroom One
Eberhard Schatz, Correlation Network, Amsterdam

Presentation

4:40 pm - 5:00 pmEpidemiology of HCV reinfection and mixed infection in the treatment setting
The Grand Ballroom One
Dr Janke Schinkel, Academic Medical Center of the University of Amsterdam

Presentation

5:00 pm - 5:20 pmManagement of HCV/HIV co-infection in the IFN-free era
The Grand Ballroom One
Professor Marina Klein, McGill University Health Centre
7:00 pm - 11:00 pmConference Dinner
Taronga Zoo

09/10/2015
8:00 am - 8:30 amRegistration
Pre-Function Area
8:30 am - 10:30 amSession K: HCV Diagnostics and Therapeutics: Where are we now and where are we going
The Grand Ballroom One
Chairperson: Dr Philip Bruggman, Head of internal medicine of Arud, Arud Centres for Addiction Medicine
Chairperson: Paata Sabelashvili, Georgian Harm Reduction Network
8:30 am - 9:00 amWill HCV therapies deliver global impact?
The Grand Ballroom One
Professor Greg Dore, UNSW

Presentation

9:00 am - 9:20 amHCV diagnostics and non-invasive liver disease assessments: What are the current tools in the toolbox and where to from here?
The Grand Ballroom One
Professor Karine Lacombe, Hospital Saint-Antoine, Paris

Presentation

9:20 am - 9:40 amStrategies for rolling out testing and treatment for PWID: Evidence from the Ukraine
The Grand Ballroom One
Ludmila Maistat, Senior Programme Manager, International HIV/AIDS Alliance

Presentation

9:40 am - 10:00 amStrategies for rolling out harm reduction, and HCV and HBV testing among PWID: Evidence from East Africa
The Grand Ballroom One
Dr Zin Mar Han, Medecins du Monde-France
10:00 am - 10:30 amMorning Tea
Exhibition Hall
10:30 am - 1:00 pmSession L: Access and implementation for all: Prevention, care and treatment
The Grand Ballroom One
Chairperson: Professor Matthew Hickman, University of Bristol
Chairperson: Nalinikanta Rajkumar, Community Network for Empowerment (CoNE)
10:30 am - 10:50 amAccess and implementation of IFN-free therapy: where to from here for low and middle income countries
The Grand Ballroom One
Niklas Luhman, Medicins du Monde

Presentation

10:50 am - 11:10 amWhat is the minimum cost to cure Hepatitis C?
The Grand Ballroom One
Andrew Hill, Liverpool University

Presentation

11:10 am - 11:30 amEfforts from the community to improve access
The Grand Ballroom One
Karyn Kaplan, Director, International Hepatitis/HIV Policy & Advocacy at Treatment Action Group (TAG)

Presentation

11:30 am - 11:40 amThe Change Project: Challenges and strategies to enhance HCV testing, linkage to care and HCV treatment among PWID
The Grand Ballroom One
11:40 am - 1:00 pmPanel Discussion: Challenges and strategies successful for enhancing HCV testing and care among PWID
The Grand Ballroom One
Chairperson: Professor Margaret Hellard, The Burnet Institute
1:00 pm - 2:30 pmLunch
The Grand Ballroom One
1:00 pm - 2:30 pmSatellite Symposium - MSD
The Grand Ballroom
2:30 pm - 5:00 pmSession M: The HCV care package: What should it include and how can we deliver it?
The Grand Ballroom One
Chairperson: Nicky Bath, NSW Ministry of Health,
Chairperson: Fifa Rahmen, Malaysian AIDS Council
2:30 pm - 2:50 pmIntegrating HCV prevention, care and treatment for PWID: A community perspective
The Grand Ballroom One
Eliot Ross Albers, International Network of People Who Use Drugs
2:50 pm - 3:10 pmHuman rights and structural barriers to treatment access
The Grand Ballroom One
Daniel Wolfe, Open Society Foundation
3:10 pm - 3:30 pmWHO guidelines on HCV screening, treatment and care: relevance for PWID
The Grand Ballroom One
Professor Margaret Hellard, The Burnet Institute
3:30 pm - 3:45 pmSession N: Rapporteur Sessions and Conference Closing
The Grand Ballroom One
3:30 pm - 3:45 pmReport from Community and Advocacy Workshop
The Grand Ballroom One
Sione Crawford, Canberra Alliance for Harm Minimisation and Advocacy
3:45 pm - 4:30 pmRapporteur report
The Grand Ballroom One
Associate Professor Jason Grebely, UNSW
4:30 pm - 4:45 pmCommunity Closing Statement
The Grand Ballroom One
Charles Henderson, New Zealand Needle Exchange Programme
4:45 pm - 5:00 pmConference Closing
The Grand Ballroom One
Professor Greg Dore, UNSW